Effectiveness of antipsychotic medication in people with intellectual disability and schizophrenia: A systematic review

Journal of Intellectual Disability Research

Volumn 43, Issue 2, 1999, Pages 94-104

  Duggan, Lorna ^a   Brylewski, J ^b  

^a Fair Mile Hospital   (United Kingdom)

^b Oxfordshire Lrng Disability NHS T   (United Kingdom)

Author keywords

Antipsychotic medication; Randomized controlled trial; Schizophrenia; Systematic review

Indexed keywords

CHLORPROMAZINE; CLOPENTHIXOL; FEBARBAMATE; LOXAPINE; MILENPERONE; NEUROLEPTIC AGENT; PENFLURIDOL; PIPAMPERONE; PROTHIPENDYL; RESERPINE; THIORIDAZINE; TIOTIXENE; TYBAMATE; UNCLASSIFIED DRUG; ZUCLOPENTHIXOL;

ARTICLE; CLINICAL TRIAL; COMORBIDITY; DATA BASE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HUMAN; INTELLECTUAL IMPAIRMENT; META ANALYSIS; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; HUMANS; MENTAL RETARDATION; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0032905191     PISSN: 09642633     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2788.1999.00181.x     Document Type: Article

References (49)

1. Aman M. G. (1984) Drugs and learning in mentally retarded persons. In: Advances in Human Psychopharmacology (eds G. D. Burrows & J. S. Werry), pp. 121-63. JAI Press, Greenwich, CT.
2. American Psychiatric Association (APA) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). APA, Washington, DC.
3. Angst J., Cornu F., Heimann H. & Steiner H. (1970) 2-chloro-11 (4-mehtylpiperazino)-dibenzo-(b,f) (1,4)oxazepin (sum 3170), ein neues Neurolepticum. Ergebnisse einer interklinischen Prufung Arzneimittelforschung 20, 967-70.
4. Bayle B. J. & Bezaury J. P. (1979) Clinical trial with a new psychotropic agent: carpipramine. Psychologie Medicale 11/12, 2695-703.
5. Brenner H. D., Alberti L., Keller F. & Schaffner I. (1984) Pharmacotherapy of agitational states in psychiatric gerontology: double-blind study: febarbamatpipamperon. Neuropsychobiology 11, 187-90.
6. Clarke D. J., Kelley S., Thinn K. & Corbett J. A. (1990) Psychotropic drugs and mental retardation: I. Disabilities and the prescription of drugs for behaviour and for epilepsy in three residential settings. Journal of Mental Deficiency Research 34, 385-95.
7. Cohen S. A. & Underwood M. T. (1994) The use of clozapine in a mentally retarded and aggressive population. Journal of Clinical Psychiatry 55, 440-4.
8. Corbett J. (1979) Psychiatric morbidity and mental retardation. In: Psychiatric Illness and Mental Handicap (eds F. E. James & R. P. Snaith), pp. 11-25. Gaskell, London.
9. De Cuyper H., van Praag H. M. & Verstraeten D. (1985) The effect of milenperone on the aggressive behavior of oligophrenic patients. A double-blind placebo-controlled study. Neuropsychobiology 13, 101-5.
10. De Guzman Rodriguez Diaz D. (1971) Experiencia clinica con conductasa. Archivos de Neurobiologia 34, 71-84.
11. Duggan L. & Brylewski J. (1998) Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review). In: The Cochrane Library, Issue 3. Update Software, Oxford.
12. Eaton L. F. & Menolascino F. J. (1982) Psychiatric disorders in the mentally retarded: types, problems and challenges. American Journal of Psychiatry 139, 1297-303.
13. Feldman H. S. & Mulinos M. G. (1966) Lack of addiction from high doses of tybamate. Journal of New Drugs 6, 354-60.
14. Foote E. S. (1958) Combined chlorpromazine and reserpine in the treatment of chronic psychotics. Journal of Mental Science 58, 201-5.
15. Fracassi M. J. & Delvecchio F. R. (1976) Evaluacion clinica de un neuroleptico semanal de mantenimiento: penfluridol (R16341). Acta Psiquiatrica y Psicologica de America Latina 22, 302-5.
16. Gillberg C., Persson E., Grufman M. & Themner U. (1986) Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. British Journal of Psychiatry 49, 68-74.
17. Gingell K. & Nadarajah J. (1994) A controlled community study of movement disorder in people with learning difficulties on antipsychotic medication. Journal of Intellectual Disability Research 37, 53-9.
18. Godleski L. S., Kerler R., Barber J. W., Glick J. L., Kellogg E., Vieweg W. V. R. & Yank G. R. (1989) Multiple versus single antipsychotic drug treatment in chronic psychosis. Journal of Nervous Mental Disease 177, 686-9.
19. Gravem A. & Elgen K. (1981) Cis (Z)-clopenthixol the neurolepticlly active isomer of clopenthixol: a presentation of five double-blind clinical investigations and other studies with cis (Z)-clopenthixol (Cisordinol, Clopixol). Acta Psychiatrica Scandinavica Supplementum 294, 5-12.
20. Heaton-Ward A. (1977) Psychosis in mental handicap. British Journal of Psychiatry 130, 525-33.
21. Heikkila L., Karsten D. & Valli K. (1981) A double-blind clinical investigation of cis (Z)-clopenthixol and clopenthixol in chronic schizophrenic patients. Acta Psychiatrica Scandinavica Supplementum 294, 25-9.
22. Jablensky A. (1986) Epidemiology of schizophrenia: a European perspective. Schizophrenia Bulletin 12, 52-73.
23. Karsten D., Kivimaki T., Linna S. L., Pollari L. & Turunen S. (1981) Neuroleptic treatment of oligophrenic patients. A double-blind multicentre trial of cis (z)-clopenthixol and haloperidol. Acta Psychiatrica Scandinavica Supplementum 294, 39-45.
24. Kuhn R., Taescher M. & Schoch J. (1966) Pharmakologische und klinische Eigenschaften eines neuen Butyrophenon-Derivates (FR33). Psychopharmacologia 9, 351-62.
25. Kumpel O. (1971) Srovnani prochlorperazinu, perfenazinu a octoclotepinu u eretickych oligofrenii. Activitas Nervosa Superior 13, 177-8.
26. Lund J. (1985) The prevalence of psychiatric morbidity in mentally retarded adults. Acta Psychiatrica Scandinavica 72, 563-70.
27. Matson J. L. & Sevin J. A. (1994) Theories of dual diagnosis in mental retardation. Journal of Consulting and Clinical Psychology 62, 61-6.
28. McKenzie M. E. & Rosswell-Harris D. (1966) A controlled trial of prothipendyl (tolnate) in mentally subnormal patients. British Journal of Psychiatry 112, 95-100.
29. Menolascino F. J., Ruedrich S. L. & Wilson T. E. (1985) Diagnosis and pharmacotherapy of schizophrenia in the retarded. Psychopharmacology Bulletin 21, 316-22.
30. Mulrow C. D. & Oxman A. D. (eds) (1996) Cochrane Collaboration Handbook. (Updated I March 1997.) In: The Cochrane Library (Database on Disk and CD-ROM). The Cochrane Collaboration. (Updated quarterly.) Update Software, Oxford.
31. Nielsen B. (1967) Oligofrene patienter behandlet med flupentixol. Nordisk Psykiatrisk Tidsskrift 21, 244-53.
32. Parson J., May J. & Menoslascino F. J. (1984) The nature and incidence of mental illness in mentally retarded individuals. In: Handbook of Mental Illness in the Mentally Retarded (eds F. J. Menolascino & J. A. Stark), pp. 000-000. Plenum Press, New York, NY.
33. Pislova J., Pisl I. & Petrova M. (1974) Clinical experience with carpipramine (Defekton). Activitas Nervosa Superior 16, 168-9.
34. Rogers D., Karki C., Bartlett C. & Pocock P. (1991) The motor disorders of mental handicap. An overlap with the motor disorders of severe psychiatric illness. British Journal of Psychiatry 158, 97-102.
35. Rutter M., Graham P. & Yule W. (1970) A neuropsychiatric study in childhood. Clinics in Developmental Medicine Nos 35/36. Heineman/Spastics, International Medical Publications, London.
36. Sachdev P. (1992) Drug induced movement disorders in institutionalised adults with mental retardation. Clinical characteristics and risk factors. Australian and New Zealand Journal of Psychiatry 26, 242-8.
37. Sajatovic M., Ramirez L. F., Kenny J. T. & Meltzer H. Y. (1994) The use of clozapine in borderline-intellectual-functioning and mentally retarded schizophrenic patients. Comprehensive Psychiatry 35, 29-33.
38. Smith D. A. & Perry P. J. (1992) Nonneuroleptic treatment of disruptive behavior in organic mental syndromes. Annals of Pharmacotherapy 26, 1400-8.
39. St-Jean A., Ban T. A. & Scott J. (1966) The effect of a protriptyline-perphenazine combination in chronic psychiatric patients. Current Therapeutic Research Clinical and Experimental 8, 483-6.
40. Tiihonen J., Hakola P., Paanila J. & Turtiainen M. (1993) Eltoprazine for aggression in schizophrenia and mental retardation. (Letter) Lancet 341, 307.
41. Varga E. & Simpson G. M. (1971) Loxapine succinate in the treatment of uncontrollable destructive behavior. Current Therapeutic Research Clinical Experimental 13, 737-42.
42. Versiani M., da Silva J. A. & Mundim F. D. (1980) Loxapine versus thioridazine in the treatment of organic psychosis. Journal of International Medical Research 8, 22-30.
43. Weinberger D. R. (1995) From neuropathology to neurodevelopment. Lancet 346, 552-7.
44. World Health Organization (WHO) (1992) The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). WHO, Geneva.
45. World Health Organization (WHO) Scientific Group on Treatment of Psychiatric Disorders (1991) Evaluation of Methods for the Treatment of Mental Disorders, WHO, Geneva.
46. Wressell S. E., Tyrer S. P. & Berney T. P. (1990) Reduction in antipsychotic drug dosage in mentally handicapped patients; a hospital study. British Journal of Psychiatry 157, 101-6.
47. Youseff H. A. & Waddington J. L. (1988) Involuntary orofacial movements in hospitalised patients with mental handicap or epilepsy; relationship to developmental/ intellectual deficit and presence or absence of long term exposure to neuroleptics. Journal of Neurology Neurosurgery and Psychiatry 51, 863-5.
48. Zwanikken G. J. (1973) Penfluridol (R16341). A long-acting oral neuroleptic, as maintenance therapy for schizophrenic and mentally retarded patients. A placebo-controlled double-blind trial. Psychiatria, Neurologia, Neurochirugia 76, 83-92.
49. Zwanikken G. J., Remans B., Dewulf P. & Amery W. (1971) Clinical evaluation of the long-acting injectable neuroleptic, fluspirilene, in the treatment of schizophrenic and mentally retarded patients. Acta Psychiatrica Scandinavica 47, 334-48.